Medical Science Liaison
Secura Bio
Medical Science Liaison
Secura Bio
Commercializes oncology therapies and develops COPIKTRA
Secura Bio was established in 2019 with a singular mission: to close the gap between innovative oncology therapies and the patients who need them most. Our high-touch approach is informed by our decades of experience shaping the impact of oncology’s largest clinical and market opportunities. We know that true impact comes from personalization and an unwavering commitment to serve patients and expand the possibilities of life-prolonging oncology medicines.
About the Role
Secura Bio is looking for an experienced Medical Science Liaison (MSL) in the Mid-West Region that will serve as a key scientific resource and strategic partner within our medical affairs team as well as cross functionally with clinical development and our marketing and sales colleagues in their region to provide clinical and scientific product education to their Health Care Providers. The MSL will focus on building and maintaining relationships with academic and community clinicians, key opinion leaders (KOLs), and research institutions in the Hematology /Oncology space, specifically rare lymphomas in support of the Medical Affairs goals and objectives. This field-based position requires a deep understanding of oncology therapeutics and the ability to communicate complex scientific information effectively to various stakeholders. Because Secura Bio operates with the urgency and innovation of a small, focused oncology company, we are looking for a self-directed, proactive, and highly adaptable MSL who can work independently, think creatively, communicate complex science clearly, and move quickly to deliver medical impact where it matters most.
Employment Type
Full-time
Reports To
Executive Director, Medical Affairs
Key Responsibilities
Required Qualifications
Preferred Qualifications
Salary
[]
Commercializes oncology therapies and develops COPIKTRA
Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.
Explore more opportunities at Secura Bio